Dublin, Jan. 29, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/lhn224/drug_discovery) has announced the addition of the "Drug Discovery Outsourcing Global Market - Forecast To 2022" report to their offering.
Over the last two decades, the Pharmaceutical/Biotech industry has undergone radical changes. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards biologics have seen a surge in the externalization and outsourcing activities.
As the industry is looking for new sources of discovery and innovation with limited resources, there is a growing preference to move towards externalization and willingness to embrace the concept of outsourcing.
Almost all the major Pharmaceutical/biotech companies are considering outsourcing as a core strategy to fill their discovery pipelines. Outsourcing companies that have precise capabilities through greater flexibility are the preferred ones. Now-a-days, the big pharma relies more on CRO's for drug discovery capabilities to stock up their pipelines.
This report provides comprehensive insights on the global drug discovery outsourcing market. The report covers all segments, global trends and emerging strategies of the outsourcing market related to drug discovery. Major Drug Discovery Outsourcing (DDO) players included in the report are Evotec, Charles River Laboratories (CRL), Pharmaceutical Product Development (PPD), WuxiApptec, ChemPartner, Syngene, Aurigene, Jubilant Biosys, Advinus, GVK Biosciences, TCG Lifesciences and AMRI.
This report caters to the need of Contract research organizations, Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Service providers and other associated stake holders to identify and analyze the potential of the DDO market. The report also provides insights on customer base, number of deals between CRO's and Pharmaceutical /biotech firms, global FTE rates, employee strength & number of companies, revenue per employee of major players, therapeutic area gap analysis and successful research collaboration outcomes of selected CRO's and Sponsors, which are likely to have an impact on the DDO market in the foreseeable future.
This report covers in-depth analysis of major players by therapeutic area of focus, capabilities, geographic presence, business models, financials, collaborations, acquisitions, various marketing strategies adopted along with insightful analysis on conferences, clusters and match making websites.
Key Topics Covered:
1 Introduction
2 Market Analysis
2.1 Research Methodology
2.2 Forecasting Model
2.3 Market Dynamics
2.4 Market Sizing
2.5 Emerging Trends & Strategies
3 Business Overview
3.1 Business Models
3.2 Business Evolution
3.3 Certifications
3.4 Dd Indicators
3.5 Pharma R&D Exp & Intensity
4 Competitor Analysis
4.1 Therapeutic Area Matrix
4.2 Global Fte Rates
4.3 Regional Revenues Vs Fte
4.4 Keyplayers (Revenue Per Employee, Customers, Deals & Ta Pie Chart, Collaboration Outcomes)
5 Leading Players
5.1 Overview
5.2 Capabilities
5.3 Therapeutic Area
5.4 Business Models
5.5 Collaborations
5.6 Acquisitions
6 Marketing Strategies
6.1 Conferences
6.1.1 Conferences -2014, 2015, 2016
6.1.2 Conference Analysis- 2014-15
6.2 Match Making Websites
6.3 Virtual Pharmaceuticals
6.4 Online Rpfs
6.5 Networking Websites
6.6 Clusters
6.7 Other Marketing Strategies
6.7.1 Website Rankings, Linkedin Followers, Google Search Volumes
Companies Mentioned
- Advinus
- AMRI Global
- Aurigene
- Charles River Laboratories
- Chempartner
- Evotec
- Gvk Biosciences
- Jubilant Biosys
- Pharmaceutical Product Development
- Syngene
- TCG Lifesciences
- Wuxiapptec
For more information visit http://www.researchandmarkets.com/research/lhn224/drug_discovery
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Drug Discovery, Consulting and Outsourcing


J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 



